SPOHN, Simon Konrad Benedict, ZAMBOGLOU, Constantinos, BÜRKLE, Sophia L., FREITAG, Martin T., BRUMBERG, Joachim Karl, ENGEL, Hannes, GAINEY, Mark, KAMPS, Marius, TONCHEVA, Paolina Tsvetanova, SPRAVE, Tetyana, KIRSTE, Simon, SIGLE, August, JILG, Cordula, GRATZKE, Christian, ADEBAHR, Sonja, MIX, Michael, BAMBERG, Fabian, ZSCHAECK, Sebastian, GHADJAR, Pirus, BALTAS, Dimos und GROSU, Anca-Ligia, 2025. Safety and quality of life of PSMA-PET- and MRI-based focal dose escalated radiotherapy for intermediate- and high-risk prostate cancer: зrimary endpoint analysis of the bi-centric phase II Hypo Focal trial (ARO2020-01). Freiburg: Universität.

Spohn, S.K.B., Zamboglou, C., Bürkle, S.L., Freitag, M.T., Brumberg, J.K., Engel, H., Gainey, M., Kamps, M., Toncheva, P.T., Sprave, T., Kirste, S., Sigle, A., Jilg, C., Gratzke, C., Adebahr, S., Mix, M., Bamberg, F., Zschaeck, S., Ghadjar, P., Baltas, D., Grosu, A.-L., 2025. Safety and quality of life of PSMA-PET- and MRI-based focal dose escalated radiotherapy for intermediate- and high-risk prostate cancer: зrimary endpoint analysis of the bi-centric phase II Hypo Focal trial (ARO2020-01). Universität, Freiburg. https://doi.org/10.1016/j.radonc.2025.110883

Spohn, S. K. B., Zamboglou, C., Bürkle, S. L., Freitag, M. T., Brumberg, J. K., Engel, H., Gainey, M., Kamps, M., Toncheva, P. T., Sprave, T., Kirste, S., Sigle, A., Jilg, C., Gratzke, C., Adebahr, S., Mix, M., Bamberg, F., Zschaeck, S., Ghadjar, P., Baltas, D., & Grosu, A.-L. (ca. 2025). Safety and quality of life of PSMA-PET- and MRI-based focal dose escalated radiotherapy for intermediate- and high-risk prostate cancer: зrimary endpoint analysis of the bi-centric phase II Hypo Focal trial (ARO2020-01) [Cd]. Universität. https://doi.org/10.1016/j.radonc.2025.110883

Spohn SKB, Zamboglou C, Bürkle SL, Freitag MT, Brumberg JK, Engel H, Gainey M, Kamps M, Toncheva PT, Sprave T, Kirste S, Sigle A, Jilg C, Gratzke C, Adebahr S, Mix M, Bamberg F, Zschaeck S, Ghadjar P, Baltas D, Grosu A-L (2025) Safety and quality of life of PSMA-PET- and MRI-based focal dose escalated radiotherapy for intermediate- and high-risk prostate cancer: зrimary endpoint analysis of the bi-centric phase II Hypo Focal trial (ARO2020-01). Universität, Freiburg

Spohn, Simon Konrad Benedict/ Zamboglou, Constantinos/ Bürkle, Sophia L./ Freitag, Martin T./ Brumberg, Joachim Karl/ Engel, Hannes/ Gainey, Mark/ Kamps, Marius/ Toncheva, Paolina Tsvetanova/ Sprave, Tetyana/ Kirste, Simon/ Sigle, August/ Jilg, Cordula/ Gratzke, Christian/ Adebahr, Sonja/ Mix, Michael/ Bamberg, Fabian/ Zschaeck, Sebastian/ Ghadjar, Pirus/ Baltas, Dimos/ Grosu, Anca-Ligia, Safety and quality of life of PSMA-PET- and MRI-based focal dose escalated radiotherapy for intermediate- and high-risk prostate cancer: зrimary endpoint analysis of the bi-centric phase II Hypo Focal trial (ARO2020-01), Freiburg 2025.